Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) on February 5, 2025. The report details a corporate governance update regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Evelyn D'An as a director of the Company, effective immediately on February 5, 2025. Key details of this appointment include:
- Committee Assignments: Ms. D'An was appointed Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee.
- Qualifications: The Board determined she is independent under NYSE American rules, meets heightened independence standards for audit and compensation committees, and qualifies as an "audit committee financial expert."
- Background: Ms. D'An is President of D'An Financial Services, a former partner at Ernst & Young (18 years), and currently serves on the boards of Zoomcar Holdings, Inc., GHD Group Pty Ltd., and Backblaze, Inc.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors. It notes that Ms. D'An will be compensated in accordance with the Company's standard non-employee director compensation plan and confirms there are no related party transactions reportable under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Ms. D'An's appointment (February 5, 2025) and her specific committee roles.
- Confirm the independence status and "audit committee financial expert" designation as stated in the filing.
- Review the attached press release (Exhibit 99.1) dated February 7, 2025, for additional context on the appointment.
- Check the Company's standard non-employee director compensation plan to understand the financial implications of this appointment.